Forscherdatenbank
![#](/application/files/8516/1901/3516/Stefan_Knapp.jpg)
Prof. Dr. Stefan Knapp
Institut für Pharmazeutische Chemie
Max-von-Laue-Str. 9
60438 Frankfurt am Main
Programme
Exploitation of Oncogenic Mechanisms (EOM)
Molecularly Targeted Therapy (MTT)
Übersicht
Our laboratory is interested in the structure based design of highly potent and inhibitors for protein interaction domains (for instance acetyl-lysine dependent bromodomains) as well as protein kinases. We support and contribute to several DKTK projects including the shared funding project PDAC (in collaboration with Prof. Dr. Jens Siveke, Essen) as well as therapeutic targeting of MYC (in collaboration with Prof. Dr. Eggert). Current projects are focussed on the development of dual HDAC/BET inhibitors as well as the development of PROTACs (protein targeting chimeras) and inhibitors that will lead to degradation of MYC. Expertise of the group ranges from the chemical synthesis of inhibitors, structure determination methods in particular using protein crystallography and the development of screening assays for medium throughput screening of low molecular weight inhibitors.